Zoë Krullaars

Zoë Krullaars

Auto-generated profile, based on publicly available information

Zoë Krullaars

Viroscience Department, Erasmus University Medical Center, 3015GD Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2023 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
MXMeng A. Xiao
Meng A. Xiao
JCJenna Cleyle
Jenna Cleyle
SYSunbin Yoo
Sunbin Yoo
MFMekayla Forrest
Mekayla Forrest
ZKZoë Krullaars
Zoë Krullaars
Thibault MesplèdeThibault Mesplède
Thibault Mesplède
Human immunodeficiency virus (HIV) treatment with antiretroviral regimens containing integrase strand transfer inhibitors such as dolutegravir (DTG) and bictegravir (BIC) offers high levels of protection against the development of drug resistance mutations. Despite this, resistance to DTG and BIC can occur through the development of the R263K integrase substitution.

29 November 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
JKJeroen van Kampen
Jeroen van Kampen
ENEls van Nood
Els van Nood
RMRizwan Mahmud
Rizwan Mahmud
ZKZoë Krullaars
Zoë Krullaars
TVTess Voskamp
Tess Voskamp
Thibault MesplèdeThibault Mesplède
Thibault Mesplède
The treatment management of HIV-2 infection presents greater challenges compared to HIV-1 infection, primarily due to inherent resistance against non-nucleoside reverse transcriptase inhibitors. Integrase strand transfer inhibitors, particularly dolutegravir, have improved treatment outcomes for people with HIV-2. Lenacapavir, a novel and potent antiretroviral capsid inhibitor offers additional therapeutic options. However, limited knowledge exists regarding HIV-2 resistance against dolutegravir and lenacapavir. We report the case of a treatment-experienced individual who did not achieve virological suppression with regimens containing dolutegravir and lenacapavir. Clinical monitoring, genotypic and phenotypic resistance assays, and in silico structural modeling were performed. Lenacapavir was added to a failing regimen of boosted darunavir, twice daily dolutegravir, and two NRTIs. Initially, this addition led to a decline in the viral load and increase in CD4+ T-cell count, despite the identification of a previously unreported combination of integrase resistance mutations. However, virological suppression was not achieved and viral load, although reduced, resumed increasing. This rebound was associated with the development of an N73D capsid substitution in HIV-2, which conferred resistance against lenacapavir. Based on cell-based assays predicting hyper-susceptibility to bictegravir, the regimen was adjusted to oral lenacapavir plus bictegravir/emtricitabine/tenofovir alafenamide, resulting in a resumption in viral load decline. Although lenacapavir demonstrated therapeutic potential, our case underscores the critical need to combine it with other fully active antiretroviral agents to prevent the rapid emergence of resistance and achieve long-term virological control in treatment-experienced individuals with HIV-2. This graphical abstract is also available at Tidbit: https://tidbitapp.io/tidbits/novel-dolutegravir-and-lenacapavir-resistance-patterns-in-human-immunodeficiency-virus-type-2-infection-a-case-report?utm_campaign=tidbitlinkshare&utm_source=IO

1 February 2023 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Closed access
RORonald J. Overmars
Ronald J. Overmars
ZKZoë Krullaars
Zoë Krullaars
Thibault MesplèdeThibault Mesplède
Thibault Mesplède
Since the first antiretroviral drug was described, the field of HIV treatment and prevention has undergone two drug-based revolutions: the first one, enabled by the virtually concomitant discovery ...

20 February 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
RMRizwan Mahmud
Rizwan Mahmud
ZKZoë Krullaars
Zoë Krullaars
JOJolieke Aleida Therese van Osch
Jolieke Aleida Therese van Osch
DRDavid Rickett
David Rickett
ZBZabrina L Brumme
Zabrina L Brumme
Thibault MesplèdeThibault Mesplède
Thibault Mesplède
The presentation of HIV peptides by the human leukocyte antigen (HLA) complex to CD8+ cytotoxic T-cells (CTLs) is critical to limit viral pathogenesis. HIV can mutate to evade HLA-restricted CTL responses and resist antiretroviral drugs, raising questions about how it balances these evolutionary pressures. Here, we used a computational approach to assess how drug resistance-associated mutations (RAMs) affect the binding of HIV-1 subtype B or C peptides to the most prevalent HLA alleles in US, European, and South African populations. We predict RAMs that may be favored in certain populations and report the under-representation of Y181C in people expressing HLA-B*57:01. This finding agreed with our computational predictions when Y181C was at the major anchor site P2, suggesting the potential relevance of our approach. Overall, our findings lay out a conceptual framework to study the implications of HLA alleles on the emergence of HIV RAMs at the individual and population levels.